Gut microbial dynamics and antibiotic resistance during rifaximin therapy in severe cirrhosis: a ProPILA-Rifax ancillary study
Frontiers in Cellular and Infection Microbiology · 2026
DOI: 10.3389/fcimb.2026.1930709 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Frontiers in Cellular and Infection Microbiology, 2026. Verfasst von Ruben Ladeira und 11 weiteren Autor:innen. Beteiligte Einrichtung: Bioinformatique et Big Data Au Service de La Santé, Oncobiologie Génétique Bioinformatique, Centre Hospitalier Universitaire (CHU) Besançon Franche-C…. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Bacteria, Drug Resistance, Bacterial, Gastrointestinal Microbiome. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Increasing evidence implicates gut dysbiosis in the pathophysiology of advanced cirrhosis. This is an ancillary study of the ProPILA-Rifax trial (NCT03069131), which evaluated rifaximin (RFX) as primary prophylaxis of spontaneous bacterial peritonitis (SBP) in patients with severe cirrhosis. Although the combined use of RFX and lactulose is effective in preventing recurrent hepatic encephalopathy (HE), its longitudinal impact on microbial communities and antibiotic resistance remains poorly characterized.
Methods
We characterized longitudinal changes in the gut microbiome of 42 patients (21 RFX, 21 placebo) over 12 months using 16S rRNA gene sequencing and culture-based phenotypic susceptibility testing. Exploratory analyses between patient bacterial profiles and clinical outcomes (disease severity, overall survival, and incidence of SBP) were conducted.
Results
RFX treatment reduced microbial richness and decreased the abundance of taxa typically enriched in advanced cirrhosis (e.g., Escherichia , Streptococcus , Veillonella ). RFX increased the proportion of Escherichia coli isolates exhibiting phenotypic resistance to rifampicin, without observed cross-resistance to ciprofloxacin or cefotaxime. In exploratory analyses, a decrease in Child-Pugh scores was correlated with enrichment of commensal taxa. Moreover, higher abundances of Ruminococcus bromii and Blautia obeum at inclusion were respectively associated with improved 12-month survival and a lower incidence of SBP.
Discussion
In severe cirrhosis, RFX profoundly alters gut microbial composition by reducing pathobiont abundance while promoting rifampicin resistance in E. coli . Furthermore, microbiota-derived signatures were associated with Child-Pugh scores, highlighting their potential to improve patient stratification.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Bioinformatique et Big Data Au Service de La Santé, Oncobiologie Génétique Bioinformatique, Centre Hospitalier Universitaire (CHU) Besançon Franche-Comté, Besançon, France.
- Université Marie et Louis Pasteur, Centre National de la Recherche Scientifique (CNRS), Unité Mixte de Recherche (UMR) 6249 Chrono-environnement, Besançon, France.
- Hygiène Hospitalière, Centre Hospitalier Universitaire (CHU) Besançon Franche-Comté, Besançon, France.
- Université Marie et Louis Pasteur, Institut National de la Santé et de la Recherche Médicale (INSERM), Unité Mixte de Recherche (UMR) 1098 Regulation of Immunity for therapeutic innovation in Graft, Host, Tumoral and in…
- Service d'Hépatologie, Centre Hospitalier Universitaire (CHU) Besançon Franche-Comté, Besançon, France.
- Service d'Hépato-Gastroentérologie, Hôpital Cabrol, Reims Cedex, France.
Zitieren
APA
Ladeira, R., Biguenet, A., Meunier, A., Gonthier, M., Di Martino, V., Pitta, A., Bardou-Jacquet, E., Jolivet-Gougeon, A., Desmarets, M., Thévenot, T., Hocquet, D., & Valot, B. (2026). Gut microbial dynamics and antibiotic resistance during rifaximin therapy in severe cirrhosis: a ProPILA-Rifax ancillary study. Frontiers in Cellular and Infection Microbiology. https://doi.org/10.3389/fcimb.2026.1930709
Vancouver
Ladeira R, Biguenet A, Meunier A, Gonthier M, Di Martino V, Pitta A, et al. Gut microbial dynamics and antibiotic resistance during rifaximin therapy in severe cirrhosis: a ProPILA-Rifax ancillary study. Frontiers in Cellular and Infection Microbiology. 2026. doi:10.3389/fcimb.2026.1930709
BibTeX
@article{Ladeira2026,
author = {Ladeira, Ruben and Biguenet, Adrien and Meunier, Alexandre and Gonthier, Marion and Di Martino, Vincent and Pitta, Anaïs and Bardou-Jacquet, Edouard and Jolivet-Gougeon, Anne and Desmarets, Maxime and Thévenot, Thierry and Hocquet, Didier and Valot, Benoit},
title = {Gut microbial dynamics and antibiotic resistance during rifaximin therapy in severe cirrhosis: a ProPILA-Rifax ancillary study},
journal = {Frontiers in Cellular and Infection Microbiology},
year = {2026},
doi = {10.3389/fcimb.2026.1930709}
}
EUVIMED